Screener
Vertex Pharmaceuticals VRTX Business Segments — Intangible asset impairment charge
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill.
The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000875320-26-000173
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Acquired in-process research and development expenses | 0.5 | 19.8 |
| Selling and other commercial expenses | 313.6 | 241.1 |
| General and administrative expenses | 180.1 | 155.3 |
| Intangible asset impairment charge | — | 379.0 |
| Interest income, net | (114.8) | (117.9) |
| Other segment items (1) | 0.2 | 19.8 |
| Provision for income taxes | 221.5 | 84.1 |
| Net income | $1,031.4 | $646.3 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vertex Pharmaceuticals's business segments — intangible asset impairment charge?
- Vertex Pharmaceuticals (VRTX) reported business segments — intangible asset impairment charge of $0 in Q1 2026.
- How has Vertex Pharmaceuticals's business segments — intangible asset impairment charge changed year-over-year?
- Vertex Pharmaceuticals's business segments — intangible asset impairment charge decreased by 100.0% year-over-year, from $379M to $0.
- What does business segments — intangible asset impairment charge mean?
- Non-cash charges recognized when the carrying value of an intangible asset, such as acquired intellectual property or licenses, exceeds its fair value. This reflects a reduction in the expected future economic benefit of an asset.
Ask your AI about Vertex Pharmaceuticals's business segments — intangible asset impairment charge.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude